Napolitano Janet 4

What Happened Janet Napolitano, a director of Vir Biotechnology, was granted equity awards on May 27, 2026: 8,000 restricted stock units (RSUs) and 16,000 derivative awards (stock-option type). Both grants show an acquisition price of $0.00 (no cash paid). The combined award totals 24,000 shares; the RSUs and the derivative awards vest in full on May 27, 2027.

Key Details

• Transaction date: 2026-05-27; reported on Form 4 filed 2026-05-28 (timely filing).
• Award amounts and prices: 8,000 RSUs @ $0.00; 16,000 derivative/option-type awards @ $0.00.
• Vesting: RSUs vest in full on May 27, 2027 (F2). The derivative awards vest and become exercisable in full on May 27, 2027 (F3).
• Shares owned after transaction: not disclosed in the filing.
• Transaction code: A = grant/award. No 10b5-1 plan, tax-withholding, or late filing flags noted.

Context These grants are compensation awards for a director rather than open-market purchases or sales. RSUs convert to shares upon vesting; the 16,000 derivative awards are stock-option–type awards that will be exercisable only after the stated vesting date. Awards are common for board service and do not by themselves indicate an immediate buying or selling signal.